nodes	percent_of_prediction	percent_of_DWPC	metapath
Nafarelin—Menopause—Vismodegib—skin cancer	0.0797	0.0797	CcSEcCtD
Nafarelin—Nasal irritation—Fluorouracil—skin cancer	0.0304	0.0304	CcSEcCtD
Nafarelin—Nasal discomfort—Fluorouracil—skin cancer	0.0184	0.0184	CcSEcCtD
Nafarelin—Pulmonary fibrosis—Bleomycin—skin cancer	0.0154	0.0154	CcSEcCtD
Nafarelin—Traumatic liver injury—Temozolomide—skin cancer	0.0153	0.0153	CcSEcCtD
Nafarelin—Ascites—Dactinomycin—skin cancer	0.0139	0.0139	CcSEcCtD
Nafarelin—Pulmonary fibrosis—Temozolomide—skin cancer	0.013	0.013	CcSEcCtD
Nafarelin—Interstitial pneumonia—Temozolomide—skin cancer	0.0118	0.0118	CcSEcCtD
Nafarelin—Transient ischaemic attack—Temozolomide—skin cancer	0.0113	0.0113	CcSEcCtD
Nafarelin—Herpes simplex—Imiquimod—skin cancer	0.0104	0.0104	CcSEcCtD
Nafarelin—Weight decreased—Vismodegib—skin cancer	0.0103	0.0103	CcSEcCtD
Nafarelin—Rash maculo-papular—Vemurafenib—skin cancer	0.0102	0.0102	CcSEcCtD
Nafarelin—Neoplasm—Vemurafenib—skin cancer	0.0101	0.0101	CcSEcCtD
Nafarelin—Interstitial lung disease—Bleomycin—skin cancer	0.00957	0.00957	CcSEcCtD
Nafarelin—Deep vein thrombosis—Temozolomide—skin cancer	0.0094	0.0094	CcSEcCtD
Nafarelin—Pulmonary fibrosis—Docetaxel—skin cancer	0.00864	0.00864	CcSEcCtD
Nafarelin—Ascites—Docetaxel—skin cancer	0.00836	0.00836	CcSEcCtD
Nafarelin—Interstitial lung disease—Temozolomide—skin cancer	0.00808	0.00808	CcSEcCtD
Nafarelin—Alopecia—Vismodegib—skin cancer	0.00803	0.00803	CcSEcCtD
Nafarelin—Hepatic function abnormal—Imiquimod—skin cancer	0.00792	0.00792	CcSEcCtD
Nafarelin—Malnutrition—Vismodegib—skin cancer	0.00791	0.00791	CcSEcCtD
Nafarelin—Interstitial pneumonia—Docetaxel—skin cancer	0.00787	0.00787	CcSEcCtD
Nafarelin—Dysgeusia—Vismodegib—skin cancer	0.00775	0.00775	CcSEcCtD
Nafarelin—Menorrhagia—Temozolomide—skin cancer	0.00772	0.00772	CcSEcCtD
Nafarelin—Vaginal haemorrhage—Temozolomide—skin cancer	0.00772	0.00772	CcSEcCtD
Nafarelin—Dry skin—Vemurafenib—skin cancer	0.00744	0.00744	CcSEcCtD
Nafarelin—Cerebrovascular accident—Imiquimod—skin cancer	0.00707	0.00707	CcSEcCtD
Nafarelin—Liver injury—Temozolomide—skin cancer	0.00679	0.00679	CcSEcCtD
Nafarelin—Myalgia—Vismodegib—skin cancer	0.00674	0.00674	CcSEcCtD
Nafarelin—Arthralgia—Vismodegib—skin cancer	0.00674	0.00674	CcSEcCtD
Nafarelin—Cystitis noninfective—Bleomycin—skin cancer	0.00662	0.00662	CcSEcCtD
Nafarelin—Breast pain—Temozolomide—skin cancer	0.00655	0.00655	CcSEcCtD
Nafarelin—Cystitis—Bleomycin—skin cancer	0.00654	0.00654	CcSEcCtD
Nafarelin—Weight decreased—Vemurafenib—skin cancer	0.00635	0.00635	CcSEcCtD
Nafarelin—Deep vein thrombosis—Docetaxel—skin cancer	0.00625	0.00625	CcSEcCtD
Nafarelin—Herpes simplex—Temozolomide—skin cancer	0.0062	0.0062	CcSEcCtD
Nafarelin—Bladder pain—Bleomycin—skin cancer	0.00613	0.00613	CcSEcCtD
Nafarelin—Musculoskeletal discomfort—Vismodegib—skin cancer	0.00588	0.00588	CcSEcCtD
Nafarelin—Sweating increased—Imiquimod—skin cancer	0.00583	0.00583	CcSEcCtD
Nafarelin—Coordination abnormal—Temozolomide—skin cancer	0.00582	0.00582	CcSEcCtD
Nafarelin—Pulmonary embolism—Temozolomide—skin cancer	0.00572	0.00572	CcSEcCtD
Nafarelin—Herpes simplex—Fluorouracil—skin cancer	0.00571	0.00571	CcSEcCtD
Nafarelin—Decreased appetite—Vismodegib—skin cancer	0.00561	0.00561	CcSEcCtD
Nafarelin—Dysuria—Imiquimod—skin cancer	0.0056	0.0056	CcSEcCtD
Nafarelin—Constipation—Vismodegib—skin cancer	0.00552	0.00552	CcSEcCtD
Nafarelin—Urinary incontinence—Temozolomide—skin cancer	0.00552	0.00552	CcSEcCtD
Nafarelin—Interstitial lung disease—Docetaxel—skin cancer	0.00537	0.00537	CcSEcCtD
Nafarelin—Depression—Imiquimod—skin cancer	0.00532	0.00532	CcSEcCtD
Nafarelin—Acute coronary syndrome—Imiquimod—skin cancer	0.00526	0.00526	CcSEcCtD
Nafarelin—Myocardial infarction—Imiquimod—skin cancer	0.00523	0.00523	CcSEcCtD
Nafarelin—Conjunctivitis—Imiquimod—skin cancer	0.00519	0.00519	CcSEcCtD
Nafarelin—Neoplasm—Temozolomide—skin cancer	0.00517	0.00517	CcSEcCtD
Nafarelin—Cerebrovascular accident—Bleomycin—skin cancer	0.00502	0.00502	CcSEcCtD
Nafarelin—Sinusitis—Imiquimod—skin cancer	0.00501	0.00501	CcSEcCtD
Nafarelin—Pleural effusion—Docetaxel—skin cancer	0.00496	0.00496	CcSEcCtD
Nafarelin—Alopecia—Vemurafenib—skin cancer	0.00496	0.00496	CcSEcCtD
Nafarelin—Malnutrition—Vemurafenib—skin cancer	0.00489	0.00489	CcSEcCtD
Nafarelin—Ear pain—Temozolomide—skin cancer	0.00486	0.00486	CcSEcCtD
Nafarelin—Rhinitis—Imiquimod—skin cancer	0.0048	0.0048	CcSEcCtD
Nafarelin—Dysgeusia—Vemurafenib—skin cancer	0.00479	0.00479	CcSEcCtD
Nafarelin—Rash maculo-papular—Fluorouracil—skin cancer	0.00479	0.00479	CcSEcCtD
Nafarelin—Asthenia—Vismodegib—skin cancer	0.00463	0.00463	CcSEcCtD
Nafarelin—Eye pain—Temozolomide—skin cancer	0.0046	0.0046	CcSEcCtD
Nafarelin—Pruritus—Vismodegib—skin cancer	0.00457	0.00457	CcSEcCtD
Nafarelin—Hot flush—Temozolomide—skin cancer	0.00444	0.00444	CcSEcCtD
Nafarelin—Diarrhoea—Vismodegib—skin cancer	0.00442	0.00442	CcSEcCtD
Nafarelin—Menopausal symptoms—Temozolomide—skin cancer	0.0044	0.0044	CcSEcCtD
Nafarelin—Alopecia—Imiquimod—skin cancer	0.00423	0.00423	CcSEcCtD
Nafarelin—Mental disorder—Imiquimod—skin cancer	0.0042	0.0042	CcSEcCtD
Nafarelin—Malnutrition—Imiquimod—skin cancer	0.00417	0.00417	CcSEcCtD
Nafarelin—Arthralgia—Vemurafenib—skin cancer	0.00416	0.00416	CcSEcCtD
Nafarelin—Myalgia—Vemurafenib—skin cancer	0.00416	0.00416	CcSEcCtD
Nafarelin—Oliguria—Docetaxel—skin cancer	0.00412	0.00412	CcSEcCtD
Nafarelin—Vomiting—Vismodegib—skin cancer	0.00411	0.00411	CcSEcCtD
Nafarelin—Affect lability—Temozolomide—skin cancer	0.00408	0.00408	CcSEcCtD
Nafarelin—Rash—Vismodegib—skin cancer	0.00407	0.00407	CcSEcCtD
Nafarelin—Dermatitis—Vismodegib—skin cancer	0.00407	0.00407	CcSEcCtD
Nafarelin—Mood swings—Temozolomide—skin cancer	0.00393	0.00393	CcSEcCtD
Nafarelin—Weight decreased—Bleomycin—skin cancer	0.00385	0.00385	CcSEcCtD
Nafarelin—Nausea—Vismodegib—skin cancer	0.00384	0.00384	CcSEcCtD
Nafarelin—Dry skin—Temozolomide—skin cancer	0.0038	0.0038	CcSEcCtD
Nafarelin—Pulmonary embolism—Docetaxel—skin cancer	0.0038	0.0038	CcSEcCtD
Nafarelin—Acute coronary syndrome—Bleomycin—skin cancer	0.00374	0.00374	CcSEcCtD
Nafarelin—Myocardial infarction—Bleomycin—skin cancer	0.00372	0.00372	CcSEcCtD
Nafarelin—Palpitations—Imiquimod—skin cancer	0.00368	0.00368	CcSEcCtD
Nafarelin—Muscular weakness—Temozolomide—skin cancer	0.00366	0.00366	CcSEcCtD
Nafarelin—Musculoskeletal discomfort—Vemurafenib—skin cancer	0.00364	0.00364	CcSEcCtD
Nafarelin—Convulsion—Imiquimod—skin cancer	0.00361	0.00361	CcSEcCtD
Nafarelin—Abdominal distension—Temozolomide—skin cancer	0.00361	0.00361	CcSEcCtD
Nafarelin—Arthralgia—Imiquimod—skin cancer	0.00355	0.00355	CcSEcCtD
Nafarelin—Myalgia—Imiquimod—skin cancer	0.00355	0.00355	CcSEcCtD
Nafarelin—Chest pain—Imiquimod—skin cancer	0.00355	0.00355	CcSEcCtD
Nafarelin—Dry skin—Fluorouracil—skin cancer	0.0035	0.0035	CcSEcCtD
Nafarelin—Sweating increased—Temozolomide—skin cancer	0.00349	0.00349	CcSEcCtD
Nafarelin—Decreased appetite—Vemurafenib—skin cancer	0.00347	0.00347	CcSEcCtD
Nafarelin—Neoplasm—Docetaxel—skin cancer	0.00344	0.00344	CcSEcCtD
Nafarelin—Constipation—Vemurafenib—skin cancer	0.00341	0.00341	CcSEcCtD
Nafarelin—Oedema—Imiquimod—skin cancer	0.0034	0.0034	CcSEcCtD
Nafarelin—Muscular weakness—Fluorouracil—skin cancer	0.00337	0.00337	CcSEcCtD
Nafarelin—Dysuria—Temozolomide—skin cancer	0.00335	0.00335	CcSEcCtD
Nafarelin—Shock—Imiquimod—skin cancer	0.00335	0.00335	CcSEcCtD
Nafarelin—Hyperhidrosis—Imiquimod—skin cancer	0.00329	0.00329	CcSEcCtD
Nafarelin—Weight increased—Temozolomide—skin cancer	0.00326	0.00326	CcSEcCtD
Nafarelin—Weight decreased—Temozolomide—skin cancer	0.00324	0.00324	CcSEcCtD
Nafarelin—Anorexia—Imiquimod—skin cancer	0.00324	0.00324	CcSEcCtD
Nafarelin—Depression—Temozolomide—skin cancer	0.00319	0.00319	CcSEcCtD
Nafarelin—Musculoskeletal discomfort—Imiquimod—skin cancer	0.0031	0.0031	CcSEcCtD
Nafarelin—Insomnia—Imiquimod—skin cancer	0.00308	0.00308	CcSEcCtD
Nafarelin—Paraesthesia—Imiquimod—skin cancer	0.00306	0.00306	CcSEcCtD
Nafarelin—Dyspnoea—Imiquimod—skin cancer	0.00303	0.00303	CcSEcCtD
Nafarelin—Alopecia—Bleomycin—skin cancer	0.00301	0.00301	CcSEcCtD
Nafarelin—Sinusitis—Temozolomide—skin cancer	0.003	0.003	CcSEcCtD
Nafarelin—Decreased appetite—Imiquimod—skin cancer	0.00296	0.00296	CcSEcCtD
Nafarelin—Hot flush—Docetaxel—skin cancer	0.00295	0.00295	CcSEcCtD
Nafarelin—Menopausal symptoms—Docetaxel—skin cancer	0.00292	0.00292	CcSEcCtD
Nafarelin—Acute coronary syndrome—Fluorouracil—skin cancer	0.0029	0.0029	CcSEcCtD
Nafarelin—Myocardial infarction—Fluorouracil—skin cancer	0.00289	0.00289	CcSEcCtD
Nafarelin—Conjunctivitis—Fluorouracil—skin cancer	0.00286	0.00286	CcSEcCtD
Nafarelin—Asthenia—Vemurafenib—skin cancer	0.00286	0.00286	CcSEcCtD
Nafarelin—Pruritus—Vemurafenib—skin cancer	0.00282	0.00282	CcSEcCtD
Nafarelin—Alopecia—Dactinomycin—skin cancer	0.0028	0.0028	CcSEcCtD
Nafarelin—Epistaxis—Fluorouracil—skin cancer	0.00278	0.00278	CcSEcCtD
Nafarelin—Sinusitis—Fluorouracil—skin cancer	0.00276	0.00276	CcSEcCtD
Nafarelin—Diarrhoea—Vemurafenib—skin cancer	0.00273	0.00273	CcSEcCtD
Nafarelin—Urticaria—Imiquimod—skin cancer	0.0027	0.0027	CcSEcCtD
Nafarelin—Rhinitis—Fluorouracil—skin cancer	0.00265	0.00265	CcSEcCtD
Nafarelin—Dizziness—Vemurafenib—skin cancer	0.00264	0.00264	CcSEcCtD
Nafarelin—Vomiting—Vemurafenib—skin cancer	0.00254	0.00254	CcSEcCtD
Nafarelin—Alopecia—Temozolomide—skin cancer	0.00254	0.00254	CcSEcCtD
Nafarelin—Dry skin—Docetaxel—skin cancer	0.00253	0.00253	CcSEcCtD
Nafarelin—Chest pain—Bleomycin—skin cancer	0.00252	0.00252	CcSEcCtD
Nafarelin—Myalgia—Bleomycin—skin cancer	0.00252	0.00252	CcSEcCtD
Nafarelin—Rash—Vemurafenib—skin cancer	0.00252	0.00252	CcSEcCtD
Nafarelin—Mental disorder—Temozolomide—skin cancer	0.00251	0.00251	CcSEcCtD
Nafarelin—Dermatitis—Vemurafenib—skin cancer	0.00251	0.00251	CcSEcCtD
Nafarelin—Headache—Vemurafenib—skin cancer	0.0025	0.0025	CcSEcCtD
Nafarelin—Malnutrition—Temozolomide—skin cancer	0.0025	0.0025	CcSEcCtD
Nafarelin—Dysgeusia—Temozolomide—skin cancer	0.00245	0.00245	CcSEcCtD
Nafarelin—Asthenia—Imiquimod—skin cancer	0.00244	0.00244	CcSEcCtD
Nafarelin—Oedema—Bleomycin—skin cancer	0.00242	0.00242	CcSEcCtD
Nafarelin—Pruritus—Imiquimod—skin cancer	0.00241	0.00241	CcSEcCtD
Nafarelin—Nausea—Vemurafenib—skin cancer	0.00237	0.00237	CcSEcCtD
Nafarelin—Myalgia—Dactinomycin—skin cancer	0.00235	0.00235	CcSEcCtD
Nafarelin—Alopecia—Fluorouracil—skin cancer	0.00234	0.00234	CcSEcCtD
Nafarelin—Diarrhoea—Imiquimod—skin cancer	0.00233	0.00233	CcSEcCtD
Nafarelin—Anorexia—Bleomycin—skin cancer	0.0023	0.0023	CcSEcCtD
Nafarelin—Oedema—Dactinomycin—skin cancer	0.00225	0.00225	CcSEcCtD
Nafarelin—Dizziness—Imiquimod—skin cancer	0.00225	0.00225	CcSEcCtD
Nafarelin—Vertigo—Temozolomide—skin cancer	0.00225	0.00225	CcSEcCtD
Nafarelin—Palpitations—Temozolomide—skin cancer	0.00221	0.00221	CcSEcCtD
Nafarelin—Musculoskeletal discomfort—Bleomycin—skin cancer	0.0022	0.0022	CcSEcCtD
Nafarelin—Paraesthesia—Bleomycin—skin cancer	0.00217	0.00217	CcSEcCtD
Nafarelin—Weight increased—Docetaxel—skin cancer	0.00217	0.00217	CcSEcCtD
Nafarelin—Convulsion—Temozolomide—skin cancer	0.00217	0.00217	CcSEcCtD
Nafarelin—Vomiting—Imiquimod—skin cancer	0.00216	0.00216	CcSEcCtD
Nafarelin—Weight decreased—Docetaxel—skin cancer	0.00216	0.00216	CcSEcCtD
Nafarelin—Dyspnoea—Bleomycin—skin cancer	0.00216	0.00216	CcSEcCtD
Nafarelin—Anorexia—Dactinomycin—skin cancer	0.00215	0.00215	CcSEcCtD
Nafarelin—Rash—Imiquimod—skin cancer	0.00215	0.00215	CcSEcCtD
Nafarelin—Dermatitis—Imiquimod—skin cancer	0.00214	0.00214	CcSEcCtD
Nafarelin—Headache—Imiquimod—skin cancer	0.00213	0.00213	CcSEcCtD
Nafarelin—Myalgia—Temozolomide—skin cancer	0.00213	0.00213	CcSEcCtD
Nafarelin—Arthralgia—Temozolomide—skin cancer	0.00213	0.00213	CcSEcCtD
Nafarelin—Decreased appetite—Bleomycin—skin cancer	0.0021	0.0021	CcSEcCtD
Nafarelin—Acute coronary syndrome—Docetaxel—skin cancer	0.0021	0.0021	CcSEcCtD
Nafarelin—Myocardial infarction—Docetaxel—skin cancer	0.00208	0.00208	CcSEcCtD
Nafarelin—Conjunctivitis—Docetaxel—skin cancer	0.00207	0.00207	CcSEcCtD
Nafarelin—Musculoskeletal discomfort—Dactinomycin—skin cancer	0.00205	0.00205	CcSEcCtD
Nafarelin—Oedema—Temozolomide—skin cancer	0.00204	0.00204	CcSEcCtD
Nafarelin—Nausea—Imiquimod—skin cancer	0.00202	0.00202	CcSEcCtD
Nafarelin—Epistaxis—Docetaxel—skin cancer	0.00201	0.00201	CcSEcCtD
Nafarelin—Convulsion—Fluorouracil—skin cancer	0.00199	0.00199	CcSEcCtD
Nafarelin—Hyperhidrosis—Temozolomide—skin cancer	0.00197	0.00197	CcSEcCtD
Nafarelin—Myalgia—Fluorouracil—skin cancer	0.00196	0.00196	CcSEcCtD
Nafarelin—Chest pain—Fluorouracil—skin cancer	0.00196	0.00196	CcSEcCtD
Nafarelin—Decreased appetite—Dactinomycin—skin cancer	0.00196	0.00196	CcSEcCtD
Nafarelin—Anorexia—Temozolomide—skin cancer	0.00194	0.00194	CcSEcCtD
Nafarelin—Urticaria—Bleomycin—skin cancer	0.00192	0.00192	CcSEcCtD
Nafarelin—Rhinitis—Docetaxel—skin cancer	0.00191	0.00191	CcSEcCtD
Nafarelin—Oedema—Fluorouracil—skin cancer	0.00188	0.00188	CcSEcCtD
Nafarelin—Musculoskeletal discomfort—Temozolomide—skin cancer	0.00186	0.00186	CcSEcCtD
Nafarelin—Insomnia—Temozolomide—skin cancer	0.00184	0.00184	CcSEcCtD
Nafarelin—Paraesthesia—Temozolomide—skin cancer	0.00183	0.00183	CcSEcCtD
Nafarelin—Dyspnoea—Temozolomide—skin cancer	0.00182	0.00182	CcSEcCtD
Nafarelin—Anorexia—Fluorouracil—skin cancer	0.00179	0.00179	CcSEcCtD
Nafarelin—Decreased appetite—Temozolomide—skin cancer	0.00177	0.00177	CcSEcCtD
Nafarelin—Constipation—Temozolomide—skin cancer	0.00174	0.00174	CcSEcCtD
Nafarelin—Asthenia—Bleomycin—skin cancer	0.00173	0.00173	CcSEcCtD
Nafarelin—Musculoskeletal discomfort—Fluorouracil—skin cancer	0.00171	0.00171	CcSEcCtD
Nafarelin—Pruritus—Bleomycin—skin cancer	0.00171	0.00171	CcSEcCtD
Nafarelin—Insomnia—Fluorouracil—skin cancer	0.0017	0.0017	CcSEcCtD
Nafarelin—Paraesthesia—Fluorouracil—skin cancer	0.00169	0.00169	CcSEcCtD
Nafarelin—Alopecia—Docetaxel—skin cancer	0.00169	0.00169	CcSEcCtD
Nafarelin—Dyspnoea—Fluorouracil—skin cancer	0.00168	0.00168	CcSEcCtD
Nafarelin—Mental disorder—Docetaxel—skin cancer	0.00167	0.00167	CcSEcCtD
Nafarelin—Malnutrition—Docetaxel—skin cancer	0.00166	0.00166	CcSEcCtD
Nafarelin—Decreased appetite—Fluorouracil—skin cancer	0.00163	0.00163	CcSEcCtD
Nafarelin—Dysgeusia—Docetaxel—skin cancer	0.00163	0.00163	CcSEcCtD
Nafarelin—Urticaria—Temozolomide—skin cancer	0.00162	0.00162	CcSEcCtD
Nafarelin—Asthenia—Dactinomycin—skin cancer	0.00162	0.00162	CcSEcCtD
Nafarelin—Diarrhoea—Dactinomycin—skin cancer	0.00154	0.00154	CcSEcCtD
Nafarelin—Vomiting—Bleomycin—skin cancer	0.00154	0.00154	CcSEcCtD
Nafarelin—Rash—Bleomycin—skin cancer	0.00152	0.00152	CcSEcCtD
Nafarelin—Dermatitis—Bleomycin—skin cancer	0.00152	0.00152	CcSEcCtD
Nafarelin—Urticaria—Fluorouracil—skin cancer	0.00149	0.00149	CcSEcCtD
Nafarelin—Palpitations—Docetaxel—skin cancer	0.00147	0.00147	CcSEcCtD
Nafarelin—Asthenia—Temozolomide—skin cancer	0.00146	0.00146	CcSEcCtD
Nafarelin—Pruritus—Temozolomide—skin cancer	0.00144	0.00144	CcSEcCtD
Nafarelin—Convulsion—Docetaxel—skin cancer	0.00144	0.00144	CcSEcCtD
Nafarelin—Nausea—Bleomycin—skin cancer	0.00144	0.00144	CcSEcCtD
Nafarelin—Vomiting—Dactinomycin—skin cancer	0.00143	0.00143	CcSEcCtD
Nafarelin—Rash—Dactinomycin—skin cancer	0.00142	0.00142	CcSEcCtD
Nafarelin—Chest pain—Docetaxel—skin cancer	0.00141	0.00141	CcSEcCtD
Nafarelin—Myalgia—Docetaxel—skin cancer	0.00141	0.00141	CcSEcCtD
Nafarelin—Arthralgia—Docetaxel—skin cancer	0.00141	0.00141	CcSEcCtD
Nafarelin—Diarrhoea—Temozolomide—skin cancer	0.0014	0.0014	CcSEcCtD
Nafarelin—Oedema—Docetaxel—skin cancer	0.00136	0.00136	CcSEcCtD
Nafarelin—Dizziness—Temozolomide—skin cancer	0.00135	0.00135	CcSEcCtD
Nafarelin—Nausea—Dactinomycin—skin cancer	0.00134	0.00134	CcSEcCtD
Nafarelin—Shock—Docetaxel—skin cancer	0.00133	0.00133	CcSEcCtD
Nafarelin—Pruritus—Fluorouracil—skin cancer	0.00133	0.00133	CcSEcCtD
Nafarelin—Vomiting—Temozolomide—skin cancer	0.0013	0.0013	CcSEcCtD
Nafarelin—Anorexia—Docetaxel—skin cancer	0.00129	0.00129	CcSEcCtD
Nafarelin—Rash—Temozolomide—skin cancer	0.00129	0.00129	CcSEcCtD
Nafarelin—Diarrhoea—Fluorouracil—skin cancer	0.00129	0.00129	CcSEcCtD
Nafarelin—Dermatitis—Temozolomide—skin cancer	0.00128	0.00128	CcSEcCtD
Nafarelin—Headache—Temozolomide—skin cancer	0.00128	0.00128	CcSEcCtD
Nafarelin—Dizziness—Fluorouracil—skin cancer	0.00124	0.00124	CcSEcCtD
Nafarelin—Musculoskeletal discomfort—Docetaxel—skin cancer	0.00124	0.00124	CcSEcCtD
Nafarelin—Insomnia—Docetaxel—skin cancer	0.00123	0.00123	CcSEcCtD
Nafarelin—Paraesthesia—Docetaxel—skin cancer	0.00122	0.00122	CcSEcCtD
Nafarelin—Nausea—Temozolomide—skin cancer	0.00121	0.00121	CcSEcCtD
Nafarelin—Dyspnoea—Docetaxel—skin cancer	0.00121	0.00121	CcSEcCtD
Nafarelin—Vomiting—Fluorouracil—skin cancer	0.00119	0.00119	CcSEcCtD
Nafarelin—Rash—Fluorouracil—skin cancer	0.00118	0.00118	CcSEcCtD
Nafarelin—Dermatitis—Fluorouracil—skin cancer	0.00118	0.00118	CcSEcCtD
Nafarelin—Decreased appetite—Docetaxel—skin cancer	0.00118	0.00118	CcSEcCtD
Nafarelin—Headache—Fluorouracil—skin cancer	0.00118	0.00118	CcSEcCtD
Nafarelin—Constipation—Docetaxel—skin cancer	0.00116	0.00116	CcSEcCtD
Nafarelin—Nausea—Fluorouracil—skin cancer	0.00112	0.00112	CcSEcCtD
Nafarelin—Asthenia—Docetaxel—skin cancer	0.000973	0.000973	CcSEcCtD
Nafarelin—Pruritus—Docetaxel—skin cancer	0.00096	0.00096	CcSEcCtD
Nafarelin—Diarrhoea—Docetaxel—skin cancer	0.000928	0.000928	CcSEcCtD
Nafarelin—Dizziness—Docetaxel—skin cancer	0.000897	0.000897	CcSEcCtD
Nafarelin—Vomiting—Docetaxel—skin cancer	0.000862	0.000862	CcSEcCtD
Nafarelin—Rash—Docetaxel—skin cancer	0.000855	0.000855	CcSEcCtD
Nafarelin—Dermatitis—Docetaxel—skin cancer	0.000854	0.000854	CcSEcCtD
Nafarelin—Headache—Docetaxel—skin cancer	0.00085	0.00085	CcSEcCtD
Nafarelin—Nausea—Docetaxel—skin cancer	0.000806	0.000806	CcSEcCtD
